Symetis has announced that the 1000th implantation of its ACURATE TA transcatheter aortic valve implantation device has taken place. The company reports that the ACURATE TA valve was first implanted in November 2009 at the Leipzig Herzzentrum by T Walther and J Kempfert.
According to a press release, the ACURATE TA was granted the CE mark in September 2011 and the first commercial implant was performed in November 2011. In April 2012, Symetis reported the clinical outcome of its SAVI Registry (n=250) showing superior results in the patient population treated in everyday clinical settings: more than 97% of patients with no relevant paravalvular leak (PVL ≤1), procedural success rate 98% and stroke rate below 2%. Since its first use, ACURATE TA has now been implanted to date in over 1,000 patients in Europe, Argentina and Japan.
The press release also reports that during the recent EACTS 2013 in Vienna (Austria), the versatility of the ACURATE TA system was further demonstrated by Michael Hilker (Universitätsklinikum Regensburg) as an effective solution to failed biological valves (valve-in-valve).